Starpharma Holdings Limited · ASX:SPL
Starpharma — Corporate Update (May 2024)
29 slides from Starpharma's corporate update, May 22, 2024

Slide 1: Business Update
ASX : SPL OTCQX : SPHRY Business Update CEO, Cheryl Maley 22 May 2024 Presented By:

Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This document is intended for investors and market participants only. This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticip

Slide 3: Our Mission
“To help patients with significant illness, such as cancer, achieve Our Mission improved health outcomes and quality of life through the application of our unique dendrimer technology.” Presented By: CEO, Cheryl Maley 3

Slide 4: Starpharma Today
Starpharma Today Corporate Overview Starpharma Value Proposition ASX:SPL Clinically validated technology Ticker Symbol OTCQX: SPHRY More than 350 patients treated with Cash Balance DEP® across multiple clinical programs. A$26.6 M (31 March 2024) Strong intellectual property position 21 active patent

Slide 5: DEP Dendrimers: Versatile, Multifunctional Delivery Platform for Therapies and Diagnostics
DEP® Dendrimers: Versatile, Multifunctional Delivery Platform for Therapies and Diagnostics Clinically validated platform Commercial Products Starpharma is the only company to More than 350 patients treated have commercialised dendrimer- across multiple clinical programs based products and multiple

Slide 6: Clinician Perspectives on the DEP Platform and Related Clinical Trials
Clinician Perspectives on the DEP® Platform and Related Clinical Trials Presented By: CEO, Cheryl Maley 6

Slide 7: Key Insights from the Business Review
Key Insights from the Business Review Portfolio Shareholders Operations Partners Capability • Broad portfolio and • Strong belief in the • Opportunity to • Extremely positive • Unique strength and optionality - previous value of the strengthen plan feedback – SPL is very broad strengths, but may den

Slide 8: Our Strategy
Our Strategy Starpharma, refocused Drive growth and shareholder value through clear prioritisation and a clear focus on delivery and execution. Presented By: CEO, Cheryl Maley 8

Slide 9: Starpharma, Refocused
Starpharma, Refocused Three key focus areas to optimise shareholder returns 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Presented By: CEO, Cheryl Maley 9

Slide 10: Starpharma, Refocused
Starpharma, Refocused Three key focus areas to optimise shareholder returns 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Presented By: CEO, Cheryl Maley 10

Slide 11: Maximise DEP Asset Value
Maximise DEP® Asset Value What has changed? Key objective: • DEP® asset and Successfully convert priority indication prioritisation opportunities to license deals • Enhanced BD capability (internal and external) Key priorities: KPIs 1. Signing partnership deals for priority assets, DEP® irinotecan •

Slide 12: Current DEP Portfolio and Next Steps
Current DEP® Portfolio and Next Steps Target Product Research Pre-clinical Phase 1 Phase 2 Goal / Next Steps indication Prostate and DEP® cabazitaxel Phase 2 complete & results reported License – Prostate, Ovarian other cancers Colorectal and Phase 2 recruitment complete & results to be reported DEP

Slide 13: DEP Clinical Assets Offer a De-risked Development Program with an Established Market Opportunity
DEP® Clinical Assets Offer a De-risked Development Program with an Established Market Opportunity Chemotherapies remain standard-of- DEP® delivery improved tolerability and Demonstrated ability to overcome care and form the backbone of anticancer efficacy in multiple anticancer treatment resistance

Slide 14: Partner for DEP Clinical Assets
Partner for DEP® Clinical Assets Potential deal structures Big Pharma or Mid-Tier or Specialty Pharma Regional Country Global e.g. EU/North America e.g. China, Japan • Single partner - • Core expertise in regional • Country-centric development one commercialisation plan regulatory guidelines and com

Slide 15: DEP Dendrimers: Bridging the Gap for Precision Cancer Radiopharmaceuticals
DEP® Dendrimers: Bridging the Gap for Precision Cancer Radiopharmaceuticals Radiopharmaceuticals help realise the potential of personalised medicine through achieving selective and targeted precision tailored to a patient’s Why we’re targeting HER2+ specific disease or biological target cancers • HE

Slide 16: Radiopharmaceuticals and ADC Development Update
Radiopharmaceuticals and ADC Development Update DEP® Radiopharmaceuticals DEP® Antibody-drug Conjugates DEP® HER2-radiodiagnostic DEP® HER2-radiotherapy DEP® HER2-ADC For whole-body localisation of HER2+ For targeted treatment of HER2+ For targeted treatment of HER2+ tumours tumours, to aid in diagn

Slide 17: Starpharma, Refocused
Starpharma, Refocused Three key focus areas to optimise shareholder returns 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Presented By: CEO, Cheryl Maley 17

Slide 18: Accelerate Early Asset Development
01 Accelerate Early Asset Development Key objectives: What is changing? • Increase # assets in early • Approach to asset candidate development identification • Increase efficiency of early • Models for partner engagement development • Pace of development Key priorities: KPIs • Advance Genentech and

Slide 19: Accelerate Early Asset Development
Accelerate Early Asset Development Increasing collaboration opportunities with the aim of successfully progressing through to partnering for value creation (e.g., development, commercialisation or asset sale) DEP® Clinical Assets RESEARCH DEVELOPMENT COMMERCIALISATION SPL Value Creation Presented By

Slide 20: Early-Stage Partnerships / Collaborations
Early-Stage Partnerships / Collaborations R&D collaboration Oncology/non-Oncology Types of ADCs Partnerships Co-development Therapeutic Radiotheranostics and Applications Collaboration Licence Drug Rescue Opportunities NCE Development Technology access Patent Extension Current Active Partnerships Pr

Slide 21: Our Strategic Partnership with Medicxi
Our Strategic Partnership with Medicxi is a leading healthcare investment firm with a track record of success, and a partner of choice for the development and commercialisation of novel therapies using Starpharma’s dendrimer technology Recap of the partnership Why this is important for SPL now • Med

Slide 22: Starpharma, Refocused
Starpharma, Refocused Three key focus areas to optimise shareholder returns 01 02 03 Maximise DEP® Accelerate early Build long-term Asset Value asset sustainability development Presented By: CEO, Cheryl Maley 22

Slide 23: Build Long-term Sustainability
01 Build Long-term Sustainability Key objectives: What is changing? • Build revenue and manage costs • Digital consumer strategy for • Create a self-sustaining Viraleze in the UK and Europe organisation • Address capability gaps Key priorities: • License revenue KPIs • Digital marketing capability t

Slide 24: Increase VivaGel BV and Viraleze Revenue
Increase VivaGel® BV and Viraleze Revenue VivaGel® BV Viraleze • Registered in more than 40 jurisdictions, • Registered in more than 35 jurisdictions*, including in the UK, Europe, Southeast Asia, including in Europe, the UK, and Asia. South Africa, Australia and New Zealand. • Awaiting TGA outcome.

Slide 25: Build Long-term Sustainability
Build Long-term Sustainability Intellectual Financials People ESG Property • Increase • Enhance • Protect • Environmental revenue: performance background IP impact licensing, culture for DEP® • Society / Viraleze and • Address • Continue to patient impact VivaGel® sales capability gaps generate new

Slide 26: Short- and Medium-Term Priorities
Short- and Medium-Term Priorities Our Immediate Short Medium Approach 0 – 9 months 9 – 18 months 18 – 24 months License DEP® asset/s Radio and ADC Development Radiotheranostic collaboration Maximise DEP® asset value Advance radiodiagnostic New collaborations New collaborations Accelerate early asset

Slide 27: Leadership Team For Q&A Session
Leadership Team For Q&A Session Cheryl Maley, BSc, DipEd, MBA, Justin Cahill, BBus, MPA, CPA Jeremy Paull, BSc (Hons), PhD Tony Eglezos, BSc (Hons), GAICD Chief Financial Officer and Company Vice President, Development and PhD, MBA Chief Executive Officer and Managing Secretary Regulatory Affairs Vi

Slide 28: Q&A
Q&A Presented By: CEO, Cheryl Maley 28

Slide 29: Thank you.
ASX : SPL OTCQX : SPHRY Thank you. Investor Relations Corporate Office Investor.Relations@Starpharma.com.au 4 – 6 Southampton Crescent Abbotsford, Victoria 3067 Australia Presented By:
Source: Internet Archive copy of archive.starpharma.com
More decks from Starpharma Holdings Limited
Shareholder Meeting (November 2026)31 slides · Nov 6, 2026
Investor Presentation (October 2026)17 slides · Oct 21, 2026
Investor Presentation (July 2026)45 slides · Jul 15, 2026
Shareholder Meeting (November 2025)35 slides · Nov 14, 2025
Australian Microcap Investment Conference 202527 slides · Oct 21, 2025
Merger or Acquisition (September 2025)8 slides · Sep 22, 2025